By Michael Dabaie

AstraZeneca PLC (AZN) said Monday an analysis of renal data from a Phase III trial showed Farxiga reduced the progression of kidney disease or renal death in patients with type 2 diabetes.

The data showed a 47% reduction with Farxiga in the relative risk of the composite renal-specific outcome of kidney function decline, end-stage renal disease, or renal death compared to placebo.

Additionally, Farxiga reduced the relative risk of a cardio-renal composite of kidney function decline, ESRD, or renal or cardiovascular death by 24% compared to placebo, AstraZeneca said.

The data are being presented at the American Diabetes Association 79th Scientific Sessions in San Francisco and simultaneously published in The Lancet Diabetes & Endocrinology.

AstraZeneca ADRs were up 0.3% premarket.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 10, 2019 08:46 ET (12:46 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.